XCancer

Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer

Description:

This study is a phase I clinical trial aimed to determine the recommended dose of 99mTc-NTP 15-5 to obtain the best tracer joints contrast on images without any toxicity.

Sponsor:

Centre Jean Perrin

Phase:

Early Phase 1

Contacts:

Florent CACHIN, Pr (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT04481230 - Click here to see study on

ClinicalTrials.gov

Inclusion
  • Age \<60 yearsCommon inclusion criteria:
  • signed written informed consent.
  • Patient with at least 31 healthy joints (based on clinical assessment)
  • Patient with non-metastatic breast cancer, hormone receptor positive, HER2 negative, with indication for adjuvant therapy with aromatase inhibitor; treatment not yet started.
  • Inclusion criteria specific to group 1:\- Patient with painful unilateral osteoarthritis of the knee as femorotibial pattern defined by a radiographic score of 0/1 from Kellgren / Lawrence and an average WOMAC score\> or equal to 4 and by minor disorders at MRI (MOCART 2.0 score\> 70).Inclusion criteria specific to group 2:
Exclusion
  • BMI\> 30
  • * Patients \<18 years of age.
  • Pregnant or lactating patient.
  • Chronic inflammatory rheumatism (rheumatoid arthritis, spondyloarthropathy, psoriatic arthritis, etc.) diffuse arthritis (at least 3 joints affected), autoimmune connectivitis, fibromyalgia.
  • History of known allergy to excipients contained in the solution of 99mTc-NTP 15-5